Tasly Pharmaceutical Group Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tianshili Pharmaceutical Group Co., Ltd. (securities code: 600535) is a leading enterprise in the internationalization of modern Chinese medicine, committed to becoming a leading and globally influential provider of pharmaceutical and health service integration solutions in China. We are "people-oriented, precise innovation", constantly promoting the progress of the pharmaceutical and health industry, allowing everyone to fully enjoy the beauty and hope of life. Headquartered in Tianjin, China, it has over 20 research capability centers worldwide and 11 production bases throughout the country. We are committed to cracking the digital password of life medicine, following the concept of "patient-centered", closely monitoring the evolution of disease spectrum, and focusing on precise innovation in major treatment fields such as cardiovascular, digestive, metabolic, tumor immunity, and neuroscience that maintain human health and life experience. We offer a rich combination of modern traditional Chinese medicine, chemical medicine, and biologically innovative drugs, breakthrough regenerative medicine, and 4D integrated health management solutions, covering all aspects of the health journey, including pre examination, early warning, prevention, diagnosis, treatment, and rehabilitation. We provide personalized and comprehensive integrated medical solutions for every patient and family, meeting the diverse needs of individual life, optimizing life experience, and improving quality of life. We continue to build an integrated platform for the entire value chain of life and health, explore and develop breakthrough therapies, address unmet clinical needs, empower medical researchers, healthcare professionals, and industry partners, and bring multidisciplinary and interdisciplinary medical innovation achievements to the benefit of patients worldwide. |
| Headquarter | Tianjin |
| Establish Date | 4/30/1998 |
| Listed Code | 600535.SH |
| Listed Date | 8/23/2002 |
| Chairman | Yan Kaijing. |
| CEO | Su Jing. |
| Website | www.taslypharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
